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Abstract 
Background. Aseptic loosening resulting from inflammatory response to the implant 
wear debris is the major cause of the late total hip arthroplasty (THA) failure. We 
examined single nucleotide polymorphisms in genes encoding for three involved 
cytokines - IL-6, TNF-α and TGF-β1 - as potential predictors of time to onset of aseptic 
instability. 
Methods. Forty one patients/45 total hip endoprostheses (same type, same surgeon) were 
followed-up for up to 18 years. They were genotyped for the IL-6 promoter (-597G→A) 
and (-572G→C), TNF-α promoter (-308G→A) and TGF-β1 signal sequence (29T→C) 
transitions. Cox regression was performed on the prosthesis survival. 
Results. Overall, 22/45 prostheses developed aseptic instability. Cumulative survival at 
10 and 15 years after THA was 95.6% and 66.6%, respectively. Effect of a particular 
polymorphic site was estimated with adjustment for sex, age at THA, reason for THA and 
the effects of other analyzed sites. Hazard ratio (HR) for genotype T/T vs. “C-allele 
carriage” at TGF-β1 site was 8.23 (95% confidence interval 1.45 to 46.8), p=0.017; or 
5.70 (1.39 to 23.4), p=0.016 when the IL-6 promoter sites were considered as a 
“combination of genotypes (-597)  (-572)”. The most prevalent combination of 
genotypes at IL-6 sites was G/A (-597)  C/C (-572). HR for this combination (vs. other 
combinations) was 5.43 (1.73 to 17.0), p=0.004 when “TGF-β1 (29T→C)” was considered 
as a 3-level factor (3 possible genotypes), and 4.92 (1.71 to 14.1), p=0.003, when TGF-β1 
site was considered as a 2-level factor (T/T and “C-allele carriage”). HR for the “A-allele 
carriage” at TNF-α (-308G→A) could not be determined (only 2 patients had the G/G 
genotype). 
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Conclusion: This preliminary study is the first to suggest TGF-β1 signal sequence 
(29T→C) and IL-6 promoter (-597G→A)  (-572G→C) transitions as predictive for time 
to onset of aseptic instability after THA. 
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Introduction 
Aseptic loosening is the major cause of the late hip endoprosthesis failure. It results from 
aseptic inflammatory reaction induced by the implant wear debris accumulating at the 
prosthesis interface, and is mediated by numerous cellular and humoral factors1. It may 
affect either the acetabular cup or the femoral stem, or both elements1-3. Aseptic loosening 
is more likely to occur earlier after arthroplasty with certain types of prosthetic 
devices/materials, for example with Endler polyethylene cups or cemented and smooth-
threaded uncemented cups as opposed to coated uncemented cups, and with cemented or 
uncoated uncemented femoral stems as opposed to coated uncemented stems1-4. Also, 
aseptic loosening is likely to occur earlier with less experienced surgeons5,6. Patients 
requiring hip arthroplasty due to developmental hip dysplasia (DDH) or complications of 
the femoral neck fracture are likely to develop aseptic loosening earlier than the patients 
with primary osteoarthritis7. High body mass index (BMI ≥30) appears to favor earlier 
onset of aseptic loosening after arthroplasty used to treat complications of the femoral 
neck fracture8. In other situations, BMI at the time of surgery seems to be irrelevant9,10. 
Patients younger than 55 years at the time of arthroplasty7, and particularly patients <46 
years of age2, are likely to develop aseptic loosening earlier than older patients. Aseptic 
loosening appears to occur earlier in men than in women9. Overall, however, the 
mentioned factors explain only a part of variability in timing of aseptic loosening after 
total hip arthroplasty (THA), which suggests a role for “individual susceptibility” to this 
complication determined by factors other than demographic or morbidity characteristics 1. 
Recently, Wilkinson and co-workers reported association of a single nucleotide 
polymorphism (SNP) in the promoter region of the tumor necrosis factor alpha (TNF-α) 
gene (-238 G→A) and the occurrence of aseptic loosening: the odds of carrying the less 
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frequent “A allele” were greater in patients who had experienced aseptic loosening than in 
patients who had not (odds ratio 1.8, 95% CI 1.0 to 3.2)10. They suggested that the genetic 
factors might help explain the variability in aseptic loosening occurrence, and genes 
encoding for the mediators of aseptic loosening appeared good candidate genes10. 
Following this logic, the current study is a preliminary investigation of further potential 
genetic “contributors” to this late complication of THA - SNPs in genes encoding for 
transforming growth factor β1 (TGF-β1), interleukin 6 (IL-6) and TNF-α . TGF-β1, IL-6 
and TNF-α are important mediators of aseptic inflammation resulting in THA instability1. 
TGF-β1 is located on chromosome 19 (q13.1-13.3)11. Polymorphisms described in this 
gene include, among others, 29T→C transition in the signal sequence12. At least in the 
middle-aged European women, carriage of the “C-allele” in this position is associated 
with lower circulating levels of TGF-β113. 
IL-6 is located on chromosome 7 (p21)14 and has several polymorphic sites including (–
597 G→A) and (–572 G→C) in the promoter region. These sites are involved in 
regulation of IL-6 production through complex interactions with other polymorphisms in 
the IL-6 promoter15,16.  
TNF-α is located on chromosome 6 (p21.1-21.3) within the human leukocyte antigen 
complex. One of the polymorphic sites is (–308 G→A) in the promoter region17. 
Homozygous genotype A/A at this site is associated with higher levels of circulating 
TNF-α and increased susceptibility to a number of inflammatory diseases18.  
In the present study, these SNPs are evaluated as potential predictors of time to onset of 
aseptic instability after total hip arthroplasty. 
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Patients and Methods 
The study was approved by the local Ethics Committee (Zagreb University School of 
Medicine Clinical Center). 
We retrospectively identified a cohort of 72 patients bearing 80 total hip 
prostheses who met the following pre-defined criteria: a) at least 12 years had elapsed 
since the surgery; b) prostheses were of the same type (Endler polyethylene uncemented 
actabular cup, Zweymueller uncemented femoral stem) and implanted by the same 
surgeon; c) they had been followed-up on regular basis (time intervals of around 12 
months, if not referring spontaneously due to subjective difficulties; d) patients consented 
to a control visit in July 2003 (“final visit”); and e) prosthesis failure (if it had occurred) 
was due to aseptic loosening19. Forty-one of these patients bearing a total of 45 prostheses 
gave written informed consents for DNA analysis and this subset is included in the 
current report. All included subjects were Caucasians, Croatian residents, with majority 
residing within the broader Zagreb area, and some were referred to our insitution from 
various other parts of Croatia (25 and 16, respectively). 
 For the hip replacement procedure, we always we used modified anterior-lateral 
approach (Watson-Jones) and placed the femoral stem in the neutral position. The follow-
up visits included clinical examination and analysis of anterior-posterior and lateral X-ray 
views according to DeLee and Charnley20: the acetabular cup contact surface area and the 
stem area were divided in 3 and 7 zones, respectively, in each view, and were inspected 
for presence of radiolucencies, osteolysis, and cup or stem migration. 
The end-point in this study was prosthesis failure due to aseptic loosening (clinical 
and/or radiological criteria for revision were met). We applied Krugluger and Eyb’s 
criteria for radiological failure21: a) level 1 – stable (visible threads or a radiolucent line of 
≤1 mm in width in no more than a single area); b) level 2 – early instability (visible 
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threads or radiolucent lines of 1-2 mm in two areas); c) level 3 – probable instability 
(visible threads or radiolucent lines of 1-2 mm in width in two or more areas; osteolytic 
defect of >2 mm) and d) level 4 – definite instability (visible threads or radiolucent lines 
of 1-2 mm in width in several areas; osteolytic defect >2 mm; endoprosthesis migration). 
Level 2 radiological findings (acetabulum or stem) where considered a prosthesis failure 
if combined with clinical symptoms. Level 3 or 4 findings were considered a failure 
regardless of the clinical symptoms. 
 Genomic DNA was extracted by proteinase K digestion followed by phenol 
extraction and ethanol precipitation of the peripheral venous white blood cells. The 
isolated DNA samples were quantified and subjected to a polymerase chain reaction 
(PCR). The SNP analysis in TGF-β1 was done by a sequence-specific-PCR based on 
mismatched 3’ nucleotide in the sense primer13. The amplicons were run through a 2% 
agarose gel stained with ethidium-bromide (0.5 ug/ml). The SNPs in IL-6 and TNF-a 
were investigated by PCR-restriction fragment length polymorphism (RFLP) analysis 
using restriction endonucleases Fok I, BsrB I (IL-6) and Nco I (TNF-α) (New England 
BioLabs) as described elsewhere16,22. Aliquots of the PCR products (6-12 uL, depending 
on the amount of the product), were digested at 37°C for 24 h. The fragments were 
separated in 10% non-denaturing polyacrylamide gel and silver stained. The primers used 
in these reactions are shown in Table 1. For all reactions, 250 ng of genomic DNA was 
used as a template and the reactions were run in Applied BiosystemsGeneAmp PCR 
System 2400. The reaction mixture (25 uL) contained dNTPs (50 µM each), 1.5 mM 
MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 8 pmol of each primer and 0.25 U of 
rTaq polymerase (TaKaRa). The reaction conditions are shown in Table 1. 
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Statistical analysis  
Each prosthesis was treated as an independent case23. Time to event was determined as 
time (years) elapsed since THA until indication for revision was made or until the final 
visit, whichever occurred first. Prostheses presenting with aseptic loosening during the 
follow-up or at the “final visit” were “failures”, and prostheses that were stable at the 
final visit were “censored data”. Proportional hazard regression was performed on the 
prosthesis survivorship data by applying proc tphreg in SAS system for Windows version 
9.1 (SAS Corp. Cary, NC, USA). Four models were analyzed. The first model (Model 1) 
included the following independents: age at the time of surgery (dichotomized as <46 
years and ≥46 years)2, sex (male or female), underlying diseases (DDH or “other”), and 
the analyzed polymorphic sites – IL-6 promoter (-597 G→A) and (-572 G→C), TNF-α 
promoter (-308 G→A) and TGF-β1 signal sequence (29T→C) – each with 3 levels (3 
possible genotypes). Second model (Model 2) differed from Model 1 in that factor “TGF-
β1 signal sequence (29T→C)” had two levels – T/T genotype or genotypes with “C allele” 
(T/C or C/C, i.e., “C allele carriage”)13. The reference genotypes at the investigated sites 
were the genotypes that prevailed within the analyzed sample. Third model (Model 3) 
differed from Model 1 in that factors “IL-6 promoter (-597 G→A)” and “IL-6 promoter (-
572 G→C)” were substituted with a single factor – “combination of genotypes at IL-6 
promoter -597 and -572 polymorphic sites”. This factor was planned to have two levels – 
the most frequent (-597)(-572) combination in the analyzed sample vs. “other 
combinations”. The last model (Model 4) was planned to be a combination of Model 2 
and Model 3. Considering the literature data9,10 and the fact that only 3 patients had BMI 
at the time of surgery >30, BMI was not included in the analyzed models. 
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Results 
General characteristics of the analyzed patients / hips are summarized in Table 2. Only 
two patients were older than 55 years at the time of THA (57 and 58 years, respectively) 
and only 3 had BMI >30 at the time of surgery (31, 33 and 34, respectively). Arthroplasty 
was mainly due to DDH. Median follow-up period was 15 years with 22/45 prostheses 
developing aseptic loosening (event rate 48.9%). Due to a small sample size, certain 
genotypes were observed in only a few patients: 5 patients (5 prostheses) had T/T 
genotype at position 29 in the TGF-β1 signal sequence, 2 subjects (2 prostheses) had G/G 
genotype at position -308 in the TNF-α promoter, 3 subjects (4 prostheses) had G/G and 6 
subjects (6 prostheses) had G/C genotype at position -572 in the IL-6 promoter (Figure 1). 
Survivorship data for the entire cohort are summarized in the life table (Table 3), and 
Figure 1 illustrates development of cumulative hazards of aseptic loosening by genotype. 
Prosthesis survivorship was analyzed in 4 separate regression models that differed in the 
number of levels per particular independent variable-polymorphic site (Table 4). “Larger” 
models (Model 1, Model 2) were borderline significant (0.05< p ≤0.1), while “smaller” 
models (Model 3, Model 4) were statistically significant (p<0.05) (Table 4). Hazard ratio 
for age at THA <46 years (vs. ≥46 years) was consistently around 2-2.5 across all models, 
and was, within the analyzed sample, not statistically significant (Model 1, Model 2) or 
was borderline significant (0.05< p ≤0.1) (Model 3, Model 4) (Table 4, Figure 2). Hazard 
ratios for female sex and reasons for THA other than DDH (vs. DDH) were consistently 
around 0.5-0.6 and were not statistically significant within the available sample (Table 4, 
Figure 2). 
With adjustment for age, sex, reason for THA and other investigated polymorphic sites, 
the main effect of factor “TGF-β1 signal sequence (29T→C)” was statistically significant 
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across all models (Table 4). The most prevalent genotype at this site within the analyzed 
sample was T/C (13 subjects, 15 prostheses) (Figure 1). When “TGF-β1 signal sequence 
(29T→C)” was considered as a 3-level factor (Model 1, Model 3), hazard ratios for 
genotype T/T (vs. T/C) were around 9 and around 6.5 in the two models, respectively 
(p<0.05) (Figure 2). In Model 2 and Model 4 “TGF-β1 signal sequence (29T→C)” was 
considered as a 2-level factor, ie, as T/T (5 subjects, 5 prostheses) vs. “C-allele carriage” 
(36 subjects, 40 prostheses) (Figure 1). Hazard ratios for genotype T/T were around 8.2 
and around 5.7 in the two models, respectively (p<0.05) (Figure 2). 
The fact that there were only 2 subjects (2 prostheses) with genotype G/G at the –308 
(G→A) site in the TNF-α promoter disabled a meaningful analysis of the potential effect 
of this polymorphism on the prosthesis survival. 
In Model 1 and Model 2 “IL-6 promoter (-597G→A)” and “IL-6 promoter (-572G→C)” 
were considered as separate 3-level factors, and their main effects were insignificant 
(Table 4). The most frequent genotypes within the analyzed sample were G/A and C/C at 
-597 and -572, respectively (Figure 1). Hazard ratios determined in respect to these 
reference genotypes showed borderline significance (0.05< p ≤0.1) for G/G at -597 (point 
estimate 0.26) and for G/C at -572 (point estimate 0.16) (Figure 2). We observed 7/9 
possible combinations of genotypes at IL-6 promoter (–597) and (–572). The most 
prevalent one was G/A (–597) | C/C (–572) (17 subjects, 17 prostheses). Among 21 
patients bearing 22 prostheses that developed aseptic loosening during the follow-up 
period, 10 subjects (10 prostheses) had this genotype. On the other hand, among 20 
subjects bearing 23 prostheses that did not develop aseptic loosening during the follow-up 
period, 7 subjects (7 prostheses) had this genotype. In Model 3 and Model 4, factors “IL-6 
promoter (–597)” and “IL-6 promoter (–572)” were replaced with a factor “combination 
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of genotypes IL-6 (-597) | (-572)” with 2 levels: G/A -597 | C/C -572 or “other”. Both 
models were significant and the main effect of this factor was significant (p<0.05, 
respectively) (Table 4). Hazard ratio for the combination G/A -597 | C/C -572 vs. “other” 
was around 5.4 (Model 3) and around 4.9 (Model 4) (p<0.05, respectively) (Figure 2). 
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Discussion 
Individual susceptibility to aseptic loosening after THA determined by patient-related 
factors other than demographic or morbidity characteristics has been recognized1. 
Recently, carriage of “A allele” at polymorphic site (–238G→A) in the TNF-α promoter 
was shown associated with higher odds of aseptic loosening10. This was the first 
documentation of genetic contribution to this late complication of THA10. The genetic 
component in this condition is likely to include modest contributions by many different 
polymorphisms, and genes encoding for cytokines involved in development of aseptic 
instability appear to be good candidate genes10. Following this logic, the current report 
addressed several further SNPs including TGF-β1 signal sequence (29T→C), IL-6 
promoter (-597G→A) and (-572G→C) and TNF-α promoter (-308 G→A). Unlike 
association studies that evaluate presence of a certain allele or a genotype and presence of 
a disease24, we investigated these sites as potential predictors of time to onset of aseptic 
loosening after THA. Each SNP (site) was assessed with adjustment for the effects of 
other SNPs and with adjustment for sex, age at surgery and reason for THA2,7,9. Since the 
analyzed group of patients was relatively young, the “cut-off” point for factor “age at 
THA” was set at 46 years2 rather than at 55 years7. Potential influences of surgeon’s skill 
and prosthetic materials on the outcome variable were controlled for by the fact that all 
prostheses were of the same type and implanted by the same experienced surgeon (>300 
THA procedures by 1985 when the first of the prostheses included in this analysis was 
implanted). We used standard methodology for detection of aseptic loosening over a 
regular and long follow-up period (shortest follow-up for a censored observation 13 
years) and well-characterized genotyping methodology. As the study was conceived as an 
exploratory one (“proof of the concept”), the outcome variable was analyzed in 4 
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alternative but pre-defined models that differed in the number of “levels” (degrees of 
freedom) for factors “TGF-β1 (29T→C)”, “IL-6 (-597G→A)” and “IL-6 (-572G→C)”. 
Repeated analysis was therefore not considered as a source of a multiplicity problem. 
The TGF-β1 signal sequence (29T→C) transition results in Leu-Pro substitution at 
position 10 in the TGF-β1 molecule and affects the peptide export efficiency11,12. 
Genotype T/C appears to prevail in the middle-aged European women13. In this 
population, genotype T/T is associated with higher levels of circulating TGF-β1 than the 
T/C or C/C genotypes (“C-allele carriage”)13. Genotype T/C prevailed in our sample, as 
well. Current data are the first to suggest that the genotype at this site is predictive for 
time to onset of aseptic instability after THA: hazard ratio for the T/T genotype vs. the 
T/C genotype or vs. the “C-allele carriage” was consistently significantly (p<0.05) greater 
than 1, suggesting a higher risk of developing aseptic loosening associated with the T/T 
genotype. Obviously, the present study is limited by a small sample and the fact that there 
were only 5 patients (5 prostheses) with the T/T genotype. However, considering the fact 
that the analyzed sample was a random one (consecutive consenting patients), the fact 
that we used a standard genotyping and radiological/clinical follow-up methodology and 
the fact that we controlled for a number of potentially confounding factors 
(inclusion/exclusion criteria, covariates), we believe that the current observation has a fair 
level of internal validity. We provide no clues about the functional relationship between 
this SNP and occurrence of aseptic loosening. It seems, however, that the apparent 
beneficial effect of higher TGF-β1 levels (and T/T genotype) on bone mineral density 
seen in “non-THA patients”13 might be overridden by some counteracting effect in the 
case of aseptic inflammation resulting in loosening of the hip replacement. 
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In contrast to a clear-cut association between the TNF-α promoter (-238 G→A) SNP and 
aseptic loosening, only a “weak trend” of association between aseptic loosening and TNF-
α promoter (-308G→A) transition was reported10. Due to the fact that there were only 
two subjects with the G/G genotype at this site in the current sample, we were unable to 
evaluate potential effects of this SNP on prosthesis survival after THA. 
Several SNPs in the IL-6 promoter (-597G→A, -572G→C, -373AnTn, and -174G→C) 
have been studied for their association with various diseases. Functional studies have 
demonstrated complex interactions among these sites in the regulation of IL-6 
transcription15. A complete linkage disequilibrium between (-597G→A) and (-174G→C) 
sites16,25-28, and no disequilibrium16,25,26,28 or a complete negative disequilibrium27 
between (-597G→A) and (-572G→C) sites have been reported in European populations. 
Studies in Caucasian European populations15,28 indicate -597/-572 haplotypes GG (around 
50%) and AG (around 40%) as the most prevalent ones. The most prevalent genotype 
combinations appear to be G/A -597G/G -572 (around 40%) and G/G -597G/G -572 
(around 30%)15,18. The fact that 17/41 subjects in the current sample had the combination 
G/A -597C/C -572 (which has not been reported in “control” European populations)15, 
and that only 4/41 subjects had the G/G  G/G combination, and none had the G/A  G/G 
combination, indicates a difference between THA patients and the “general Caucasian 
European” population. Considering that most of our patients suffered from developmental 
dysplasia of the hip (DDH), this may indicate an association between IL-6 promoter SNPs 
and DDH. Combination of genotypes G/G | G/G | G/G at -597, -572 and -174 appears to 
be predictive for a better kidney allograft survival: it is associated with lower hazard of 
allograft rejection than other combinations taken cumulatively28. In the current report, 
individual influences of the IL-6 (-597) and (-572) sites/genotypes did not appear to have 
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a relevant effect on the prosthesis survival. A similar “lack of the effect” of -597 or -572 
genotypes on kidney allograft survival has been reported15. However, the G/A  C/C 
combination of genotypes at these two sites was associated with a markedly increased risk 
of aseptic loosening (vs. other combinations cumulatively) (DDH included as a 
covariate). Hence, the current data are the first to suggest that SNPs/genotypes in the IL-6 
promoter might be predictive for the time to onset of aseptic instability after THA. 
Functional links between these SNPs and aseptic loosening await further investigations. 
In conclusion, the results of this preliminary study point out TGF-β1 signal sequence 
(29T→C) and IL-6 promoter (-597G→A) and (-572G→C) transitions as predictive for 
time to onset of aseptic instability after THA and suggest that these polymorphic sites 
deserve to be further investigated in larger studies that would enable conclusions on 
prevalence of particular genotypes or alleles among THA patients and their clinical 
relevance.  
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Table 1. Primers, cycle conditions, fragment lengths, polymorphism position, enzymes and digested fragments determining the PCR and RFLP 
methods.  
Gen Primers No of cycles / 
annealing temperature 
Fragment 
length 
Polymorphism Enzymes Digested 
fragment 
length 
Ref. 
IL-6 Sense primer 
5'- GCA ACT TTG AGT GTG TCA CG-3' 
35 cycles / at 57°C 169 bp -597A→C Fok 1 122/47 16 
 Anti sense primer 
5'-TGA CGT GAT GGA TGC AAC AC-3' 
35 cycles / at 57°C 163 bp -572G→C BsrB 1 101/62 16 
TGF-ß1 Sense primer 1 
5'-CTC CGG GCT GCG GCT GCT GCT-3' 
40 cycles / at 62°C 346 bp T29 →C   13 
 Sense primer 2 
5'-CTC CGG GCT GCG GCT GCT GCC-3' 
40 cycles / at 62°C      
 Anti sense primer 
5' –GTT GTG GGT TTC CAC CAT TAG-3' 
40 cycles / at 62°C      
TNF-α Sense primer 
5'-AGG CAA TAG GTT TTG AGG GCC AT-3' 
35 cycles / at 57°C 107 bp -308G→A Nco 1 42/65 22 
 Anti sense primer 
5'-TCC TCC CTG CTC CGA TTC CG-3' 
35 cycles / at 57°C      
 
 
  
Table 2. General characteristics of the analyzed patients and hips. Data are counts or 
median (range). 
Number of patients, sex (M/F) 41 (13/28) 
Number of hips, sex (M/F) 45 (15/30) 
Age (years) at the time of surgery (by hip)  44 (26-58) 
Distribution by age at the time of surgery (by hip) 
- < 46 years 
- ≥ 46 years 
 
27 
18 
Body mass index at the time of surgery (by hip) 25 (20-34) 
Causes leading to hip arthroplasty (by hip): 
- developmental dysplasia of the hip (DDH) 
- idiopathic aseptic necrosis of the femoral head 
- trauma (fracture, epiphyseolysis) 
- Mb Bechterew 
 
31 
6 
4 
4 
Follow-up period (years) (by hip) 15 (5-18) 
Prostheses with aseptic loosening  22 
Isolated aseptic loosening of the cup  15 
Aseptic loosening of the cup and the stem  7 
 
 
 
 
 
 
 
 
 
  
Table 3. Life table for the 45 analyzed endoprotheses. Time since arthroplasty is 
given as one-year intervals in line with the frequency of the follow-up visits. 
Years since 
surgery  
At risk 
(n) 
Failed 
(n) 
Censored 
(n) 
Cumulative 
survival 
Cumulative hazard 
(95% CI) 
1 45 0 0 1 0 
2 45 0 0 1 0 
3 45 0 0 1 0 
4 45 0 0 1 0 
5 45 0 0 1 0 
6 45 1 0 1 0.022 (0.003 to 0.158) 
7 44 0 0 0.978 0.022 (0.003 to 0.158) 
8 44 1 0 0.978 0.045 (0.011 to 0.180) 
9 43 0 0 0.956 0.045 (0.011 to 0.180) 
10 43 2 0 0.956 0.091 (0.034 to 0.244) 
11 41 3 0 0.911 0.165 (0.078 to 0.345) 
12 38 1 0 0.844 0.191 (0.095 to 0.382) 
13 37 4 0 0.822 0.299 (0.170 to 0.527) 
14 33 3 1 0.733 0.391 (0.235 to 0.651) 
15 29 1 5 0.666 0.429 (0.262 to 0.704) 
16 23 2 5 0.641 0.527 (0.326 to 0.850) 
17 16 1 2 0.578 0.593 (0.368 to 0.957) 
18 13 1 8 0.539 0.704 (0.424 to 1.170) 
18 + 4 2 2 0.480 1.371 (0.666 to 2.842) 
Failed= prostheses presenting with aseptic loosening; censored= “final visit” 
performed at the particular time since arthroplasty, no signs of aseptic loosening. 
 
 
 
 
 
 
 
  
Table 4. Summary of proportional hazard regression on time to onset of aseptic instability after total hip arthroplasty in four analyzed 
models. Likelihood ratio (LR) test was used to assess the significance of a model. Type III tests based on Wald statistics assessed the 
effects of individual factors (“main effects”). Factors age and disease were dichotomized (see Patients and Methods). In Model 1, each 
factor-polymorphic site had 3 levels (3 possible genotypes). In Model 2, factor TGF-β1 (29) had 2 levels: “T/T” or “C-allele carriage”. 
In Model 3, factors IL-6 (–597) and IL-6 (–572) were replaced by a single factor – combination of genotypes at (-597) and (-572), with 
two levels: “G/A (-597)  C/C (-572)”, which was the most frequent combination in the analyzed sample or “other”. Model 4 was a 
combination of Model 2 and Model 3. 
Model 1 
LR test   df 11, p=0.082 
 Model 2 
LR test   df 10, p=0.058 
 Model 3 
LR test   df 8, p=0.038 
 Model 4 
LR test   df 7, p=0.022 
Effects df P  Effects df P  Effects df P  Effects df P 
Age  1 0.199  Age  1 0.220  Age  1 0.068  Age  1 0.076 
Disease 1 0.448  Disease 1 0.453  Disease 1 0.467  Disease 1 0.432 
Sex 1 0.469  Sex 1 0.450  Sex 1 0.381  Sex 1 0.352 
IL-6 (–597) 2 0.143  IL-6 (–597) 2 0.142  IL-6 (-597  -572) 1 0.004  IL-6 (-597  -572) 1 0.003 
IL-6 (–572) 2 0.233  IL-6 (–572) 2 0.228  TGF-β1 (29) 2 0.049  TGF-β1 (29) 1 0.016 
TGF-β1 (29) 2 0.055  TGF-β1 (29) 1 0.017  TNF-α (–308) 2 0.781  TNF-α (–308) 2 0.792 
TNF-α (–308) 2 0.999  TNF-α (–308) 2 0.999         
 
  
Figure 1. Prevalence of genotypes at the investigated sites and cumulative hazard of aseptic 
loosening over time after total hip arthroplasty by genotype. Cumulative hazard is from the life-
table analysis. 
 
 
 
  
 
 
 
Figure 2. Hazard ratios (HR) from the proportional hazard regression analysis of time to onset of 
aseptic loosening after total hip arthroplasty in four models depicted in Table 4. For a particular 
factor-polymorphic site, HR was determined in respect to the most prevalent genotype in the 
analyzed sample. When factor “TGF-β1 (29T→C)” had two levels (Model 2, Model 4), HR was 
determined for genotype T/T in respect to “C-allele carriage”. When factor “combination of 
genotypes IL-6 (-597)  (-572)” with two levels was included in the analysis (Model 3, Model 4), 
HR was determined for the combination G/A (-597)  C/C (-572), which was the most frequent one 
in the analyzed sample, in respect to “other combinations”. Statistically significant or borderline 
significant HRs are presented graphically and numerically. 
* G/G genotype at this site was found only for 2 hips, both followed-up for 17 years and not 
developing aseptic loosening (“censored”). 
 
  
 
